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oRIGINAL ARTICLE
Introduction: Malignant pleural mesothelioma (MPM) can reduce 
lung function by entrapping lung parenchyma via a rind of tumor 
with or without concurrent effusion. Radical pleurectomy (RP) 
allows expansion of the trapped lung. The purpose of this study was 
to investigate changes in pulmonary function and lung perfusion in 
patients undergoing RP.
Methods: In a prospective, nonrandomized study, all patients 
with histologically proven MPM were evaluated from January to 
December 2010 for trimodality therapy including RP as surgical pro-
cedure. Pulmonary-function tests and perfusion scans were obtained 
before and 2 months after RP. Primary end points were pulmonary 
function (forced vital capacity [FVC], forced expiratory volume in 
1 second [FEV1]) and ipsilateral lung perfusion.
Results: Sixteen out of 25 consecutive patients (age 68.8±8.9 years) 
were enrolled in the study. Macroscopic complete resection could be 
achieved in 13 patients (81.3%). Diaphragm resection was necessary 
in 5 patients. Significant postsurgical improvement of pulmonary 
function at 2 months was observed for FVC and FEV1 (both abso-
lute and percentage of predicted values) and ipsilateral perfusion (p < 
0.001). Avoidance of diaphragm resection was associated with greater 
increase in FVC (+34.6±17.0% versus +13.5±5.4%; p = 0.002) and 
FEV1 (+29.2±18.1% versus +12.1±6.4%; p = 0.015), respectively.
Conclusions: Lung-sparing RP leads to significant improvement 
of pulmonary function and perfusion after a recovery time of 2 
months. Functional results are better after preservation of the dia-
phragm. Preservation of physiological reserve via lung-sparing RP 
might allow patients with MPM to be eligible for further therapeutic 
options in the long term.
Key Words: Mesothelioma, Pleurectomy, Decortication, Perfusion, 
Pulmonary function.
(J Thorac Oncol. 2012;7: 900–905)
Malignant pleural mesothelioma (MPM) is an aggressive and rapidly fatal malignancy of the pleura. MPM can 
reduce lung function by entrapping lung parenchyma via a 
rind of tumor with or without concurrent effusion.
originally, pleurectomy/decortication (P/D) was a pal-
liative option to control MPM-related pleural effusions.1 
However P/D or radical pleurectomy (RP) within a multimo-
dality therapy concept seems to be an alternative for patients 
with MPM unsuitable or unwilling to undergo extrapleural 
pneumonectomy (EPP).2,3 RP is lung sparing and allows for 
re-expansion of trapped lung. Thus RP, as a surgical strat-
egy within a multimodality therapy concept for patients with 
MPM, could be associated with the preservation or improve-
ment of physiological reserve and thus allow patients to be 
eligible for multimodality approaches.2
There are several studies reporting on the changes of 
pulmonary function before and after lung decortication for 
chronic empyema.4,5 In general, studies demonstrated improve-
ment in pulmonary function after surgery. In contrast, there is, 
to the best of our knowledge, no data on the effects of RP 
or P/D for MPM on lung function. The purpose of this study 
was to investigate the effects of RP on the objective measures 
of pulmonary function and lung perfusion in patients with 
MPM.
PATIENTS AND METHODS
At a single tertiary referral center, all patients with non-
specific unilateral pleural effusion underwent videothoracoscopic 
evaluation including pleural-fluid evacuation and biopsy of the 
pleura. In patients with histologically proven MPM the drainage 
was removed without pleurodesis. All patients with MPM were 
evaluated for trimodality therapy with curative intent, as described 
previously.2 In brief, the multimodality therapy included RP fol-
lowed by four cycles of cisplatin/pemetrexed and radiation of the 
chest wall. Inclusion criteria were as follows:
Histologically confirmed diagnosis of MPM.• 
Clinical T1-3, N0-2, M0 disease.• 
No prior treatment for MPM.• 
Adequate cardio-pulmonary reserve.• 
Adequate renal and liver function.• 
Within this patient cohort, pulmonary-function tests 
(PFTs) and perfusion scans were obtained before and 2 months 
after RP in a prospective, nonrandomized study over a 1-year-
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period from January to December 2010. The primary end 
points in the present study were the effects on lung-function 
parameters measured by bodyplethysmography (forced expira-
tory volume in 1 second [FEV1], forced vital capacity [FVC], 
FEV1/FVC ratio) and ipsilateral lung perfusion. The bodypl-
ethysmographic measurements were performed between the 
videothoracoscopy and RP (pre PFTs) and 2 months after 
RP (post PFTs) according to the American Thoracic Society 
criteria and established standards.6 The secondary outcomes 
included improvement of 10% or more in FEV1 (% predicted), 
and operative morbidity and mortality.
The definition of P/D or RP remains variable. The 
International Association for the Study of Lung Cancer 
International Staging Committee and the International 
Mesothelioma Interest Group defined P/D as a surgical pro-
cedure to remove all macroscopic tumor involving the parietal 
and visceral pleura. The term “extended” P/D is implemented 
when the diaphragm or pericardium is resected.7 on the con-
trary, we define RP as a surgical approach that involves resec-
tion of the visceral and parietal pleura while preserving the 
lung. We always try to resect the visceral pleura even if there 
are no visible tumor spots. However, wedge resections are car-
ried out in the event of deep infiltration of the lung paren-
chyma. We aim to preserve the phrenic nerve, pericardium, 
and diaphragm as maximally possible from oncological point 
of view. Generally, we resect the diaphragmatic pleura leaving 
only the bare muscle fibers. Furthermore, the pericardium is 
split and only the fibrous part is resected whereas the serous 
part is left intact. Nonetheless, partial or total resection and 
reconstruction of the diaphragm and pericardium can be per-
formed depending on the intraoperative findings.
Nicotine cessation was a precondition for surgery. 
Intensive chest physiotherapy program was administered, 
including deep-breathing exercises and incentive spirometry 
using a volume-oriented device (Voldyne 5000 Volumetric 
Exerciser, Teleflex Medical GmbH, Kernen, Germany) at 
least six times a day for 10 minutes each time during the hos-
pitalization. The patients had to become acquainted with the 
mechanism of active cycle of breathing, forced cough, and 
expiratory techniques, respectively. The learning of these 
techniques was controlled in the pulmonary rehabilitation 
group daily session under the supervision of a respiratory 
therapist. Aerosol therapy was performed at least twice-daily. 
In addition, mucus clearance was facilitated by a flutter valve 
device (VRP1 Flutter, Tyco Healthcare Deutschland GmbH, 
Neustadt/Donau, Germany). The exercise compliance was 
enforced both by nurses and surgeons/physicians, respectively. 
Furthermore, patients had to continue their exercise regimen 
after discharge from the hospital.
Institutional review board approval was obtained for 
this study. The trimodality treatment was registered with 
ClinicalTrials.gov (identifier NCT01343264). Written con-
sent was obtained from each study patient. The study was 
conducted according to the revised Declaration of Helsinki 
and the requirements of good clinical practice.
Means and standard deviations are used for description 
of continuous measures. Descriptive statistics for discrete 
variables are presented as frequencies and percentages. The 
outcomes were assessed using Student’s t tests or Fisher’s exact 
tests as appropriate. We used descriptive statistics to investi-
gate possible treatment effects because of the small sample 
size in this pilot study. We used two approaches to analyze 
treatment effects descriptively. We evaluated Cohen’s d (effect-
size estimates) using change values in outcome measures. 
Depending on the effect size, the effect was considered “small 
effect” (Cohen’s d of 0.2), “medium effect” (Cohen’s d of 0.5), 
and “large effect” (Cohen’s d of 0.8), respectively. Linear regres-
sion analysis was performed to analyze the relation between 
preoperative and postoperative pulmonary-function data. 
A p value less than 0.05 dividing with the number of factors 
examined (Bonferroni adjustment), was considered statisti-
cally significant. Data were stored using Excel (Microsoft, 
Seattle, WA). SPSS 15.0 software (SPSS Inc., Chicago, IL) 
was used to analyze the data.
RESULTS
During the study period, 25 patients with histologically 
confirmed MPM were referred to our Department of Thoracic 
Surgery for cardio-pulmonary evaluation before RP. of these 
evaluated patients, 16 study subjects (age 68.8 ± 8.9 years, 
14 men, Table 1) were eligible for RP and entered the study.
The reasons for the exclusion were as follows:
Metastatic disease (•  n = 1).
ongoing palliative chemotherapy (•  n = 1).
Complete remission after induction chemotherapy • 
(n = 1).
Rapid progressive disease (•  n = 1).
Diffuse chest wall infiltration (•  n = 2).
Impaired cardio-pulmonary reserve (•  n = 3).
Surgical morbidity was 43.8 % (7 of 16). The complications 
included tachyarrhythmia (n = 3), reoperation for bleeding (n = 
1), pneumonia (n = 1), prolonged air leak (n = 1) and chylothorax 
(n = 1), respectively. No mortality occurred. Macroscopic com-
plete resection could be achieved in 13 patients (81.3%). Resection 
of the diaphragm was necessary in 5 patients (31.3%). Twelve 
patients had advanced disease at International Mesothelioma 
Interest Group (IMIG) stages III/IV (75%). Primary histology 
was epithelial (87.5%).
Preoperative spirometry showed a mean FVC (% 
predicted) of 54.7±9.9 %, a mean FEV1 (% predicted) of 
60.2%±10.3 % and a mean FEV1/FVC-ratio 0.82±0.08, reflec-
tive of a moderate restrictive ventilatory defect. Ipsilateral per-
fusion was reduced to 29.2%±6.5%. Significant postsurgical 
improvement of pulmonary function was observed for FVC 
(L), FVC (%), FEV1 (L) FEV1 (%), and ipsilateral perfusion 
(Table 2, Figs. 1 and 2). The effect size was high in all measure-
ments. The average increases were in post–pre-FVC +28.0% 
(+3.5% to +59.0%), post–pre-FEV1 + 23.9% (+1.5% to +61.5%) 
and post–pre-perfusion + 37.8% (+8.7% to +150.0%), respec-
tively. The postoperative FVC (% predicted) of 68.9%±9.1 
%, mean FEV1 (% predicted) of 73.6%±11.4 % and a mean 
FEV1/FVC-ratio 0.80±0.06 demonstrated the improvement to 
a mild restrictive ventilatory defect 2 months after RP. Thirteen 
patients (81.3%) had an improvement of 10% or more in FEV1 
(% predicted). No significant changes were observed with regard 
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to the blood gas analysis. Laterality of the disease, complete-
ness of resection and histology had no significant impact on 
pulmonary function or perfusion scan, respectively.
Avoidance of the diaphragm resection was associ-
ated with greater increase in FVC (=Post–pre-FVC (%) 
+ 34.6%±17.0% versus +13.5%±5.4%; p = 0.002) and FEV1 
(=Post–pre-FEV1 (%) +29.2%±18.1% versus + 12.1±6.4%; 
p = 0.015), respectively. The presence of the diaphragm resec-
tion had no significant effect on the lung perfusion.
In a linear regression analysis a lower preoperative 
FVC (% predicted) or FEV1 (% predicted) was associated 
with higher relative increases in FVC or FEV1 after RP 
(p < 0.02 for both, Fig. 3). A higher preoperative FEV1/
FVC-ratio was associated with a greater relative increase in 
FVC than in FEV1, whereas a lower preoperative FEV1/
FVC-ratio was associated with a greater relative increase in 
FEV1 then in FVC (p = 0.01, correlation coefficient r = 0.65, 
Fig. 4).
DISCUSSION
To our knowledge, this is the first study reporting on the 
effects of RP or P/D on objective measures of pulmonary func-
tion and ipsilateral lung perfusion. We found that lung-sparing 
RP leads to significant improvement of pulmonary function 
and perfusion after a recovery time of 2 months. Functional 
results are better after preservation of the diaphragm. This is 
important information for the clinician evaluating a patient 
regarding candidacy for RP.
Generally, studies reporting on the changes of pulmo-
nary function before and after lung decortication for chronic 
empyema have shown improvements of FEV1 and FVC 
in the range of +18.6% to +30.5% and +19.2% to +28.8%, 
TABLE 1. Patients’ Demographics
# Patients’ Age Sex Laterality Histology IMIG Stage
Resection of 
Diaphragm
Macroscopic 
Completeness of 
Resection
1 70 Male Right Sarcomatoid III (pT3N0) No Yes
2 79 Male Left Epitheloid I (pT1bN0) No Yes
3 68 Male Left Epitheloid III (pT3N2) No Yes
4 75 Male Right Epitheloid III (pT3N0) Yes Yes
5 57 Female Left Epitheloid IV (pT4N2) Yes No
6 59 Male Right Epitheloid IV (pT4N2) No No
7 58 Male Left Epitheloid III (pT3pN0) No Yes
8 51 Female Left Sarcomatoid I (pT1bN0) No No
9 63 Male Right Epitheloid IV (pT2N3) Yes Yes
10 74 Male Right Epitheloid III (pT3N1) Yes Yes
11 71 Male Right Epitheloid II (pT2N0) No Yes
12 82 Male Right Epitheloid III (pT3N0) No Yes
13 69 Male Right Epitheloid III (pT3N0) Yes Yes
14 71 Male Left Epitheloid III (pT3N1) No Yes
15 76 Male Right Epitheloid II (pT2N0) No Yes
16 77 Male Left Epitheloid III (pT3N0) No Yes
TABLE 2. Changes in Pulmonary Function and Ipsilateral Perfusion
Preoperative
Value
[range]
Postoperative
Value
[range]
p
Value Cohen’s d
Effect
Size
FVC (Liter) 2.18±0.49
[1.30–3.11]
2.73±0.55
[1.89–3.77]
< 0.001* 1.06 Large
FVC (%) 54.7±9.9
[39–69]
68.9±9.1
[53–83]
< 0.001* 1.49 Large
FEV1 (Liter) 1.79±0.45
[1.05–2.91]
2.18±0.50
[1.49–3.65]
< 0.001* 0.81 Large
FEV1 (%) 60.2±10.3
[40–79]
73.6±11.4
[58–91]
< 0.001* 1.23 Large
FEV1 / FVC 0.82±0.08
[0.72–1.00]
0.80±0.06
[0.72–0.97]
0.12 0.44 Medium
Ipsilateral
Perfusion (%)
29.2±6.5
[16–37]
38.5±3.5
[25–43]
< 0.001* 1.78 Large
* Significant, p < 0.05/6 (Bonferroni adjustment). 
FVC, forced vital capacity; FEV1, forced expiratory volume.
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respectively.4,5 The mean increase of FEV1 and FVC in the 
present study was +23.9% and +28.0%, respectively. An on-
average moderate restrictive ventilatory defect was present 
preoperatively. However, an improvement to an-only mild 
restrictive ventilatory defect at 2 months after RP was real-
ized. Whether the improvements in pulmonary function after 
RP persist in the long-term is, however, not answered by this 
investigation. We studied the restoration of the respiratory 
function 2 months after surgery. Long-term comparisons of 
the pulmonary function in the rapidly fatal disease of MPM 
are difficult because the 1-year overall survival rate in general 
is 55%.8 Nevertheless, quantitative measurement of lung reex-
pansion in MPM patients undergoing P/D showed that there 
are no statistically significant changes in ipsilateral lung vol-
ume between 1- and 4-month-postsurgical computer tomogra-
phy scans.9 This suggests that improvements in lung function 
persist beyond 2 months after surgery.9
The most significant respiratory muscle is the diaphragm. 
Resection of the diaphragm, phrenic nerve injury, or sacrifice 
of the phrenic nerve causes the loss of diaphragmatic function. 
In otherwise healthy patients, unilateral diaphragm paralysis 
results in the loss of FVC and FEV1 of approximately 25% 
and 30%, respectively.10 MPM might involve the diaphragm 
by direct extension. The RP technique usually allows the iso-
lated resection of the diaphragmatic pleura without impairment 
of the diaphragm function. If the tumor extension involves the 
diaphragm muscle, diaphragm resection and reconstruction 
might be necessary. The sacrifice of the phrenic nerve might be 
indicated in case of phrenic nerve extension of the tumor bulk. 
In our study, preservation of diaphragm function was associ-
ated with greater increase in FVC and FEV1 of approximately 
23.1% and 17.1%, respectively. Thus, the preservation of the 
diaphragm should be attempted whenever technically and onco-
logically feasible.
In general, approximately 85% of the patients die 
within the first 3 months in event of the recurrence of MPM.11 
However, several phase-III trials demonstrated that second-
line chemotherapy is associated with significantly prolonged FIGURE 2. Box plot of changes in ipsilateral perfusion scans. 
A B
FIGURE 3. Scatter plot of preoperative FVC (%-predicted) against relative increase in FVC after RP and preoperative 
FEV1 (%-predicted) against relative increase in FEV1 after RP (r = correlation coefficient). FVC, forced vital capacity; FEV1, 
forced expiratory volume; RP, radical pleurectomy.
FIGURE 1. Box plot of changes in pulmonary function. 
FVC, forced vital capacity; FEV1, forced expiratory volume.
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survival in the management of MPM.12,13 No more than 25% 
of the patients receive additional chemotherapy after EPP and 
multimodality treatments.14 on contrary, 64% of the patients 
with MPM recurrence after RP were found to be eligible for 
further therapy options after RP.2 Patients managed with RP 
and first-line chemotherapy are commonly still in good perfor-
mance status when radiological progression of MPM is docu-
mented. Clinical benefit from further therapy might be seen in 
65% of patients with MPM recurrence.15 Thus, preservation 
of the cardio-pulmonary reserve might be a precondition to 
being eligible for further therapy options such as second-line 
and third-line therapies, and novel cytostatic drugs or vaccines 
currently under investigation.16
Another important issue is quality of life (QoL) after 
possible surgery. Even if we did not evaluate the QoL in the 
present study, physical functioning and dyspnea status play a 
major role in the evaluation of QoL.17 Reduced pulmonary-
function status after surgery is associated with decrements 
in QoL in thoracic malignancies.18 Furthermore, FVC was 
correlated with patient-reported disease-related symptoms 
and health-related QoL (HRQoL) using the Lung Cancer 
Symptom Score-Mesothelioma.19A higher baseline FVC 
was associated with higher baseline Karnofsky Performance 
Status and correlated with normal activity scores, as well. 
These functional factors can be significantly influenced by 
the type of resection. We have shown that parenchyma-sav-
ing RP is associated with the improvement of lung function. 
The available data and the results of the present study would 
suggest that a surgical strategy of limiting loss of lung func-
tion may result in a better preservation of QoL. Nonetheless, 
pulmonary-function tests alone cannot substitute QoL- or 
subjective dyspnea-scoring evaluations.20 Thus, QoL- and 
dyspnea-scoring assessments are planned for future trials at 
our institution.
In general, mortality rates for RP are in the range of 
2% to 5.8%.2,21 We observed no surgical mortality. Surgical 
morbidity was 43.8 % and the complications were not life-
threatening. However, preoperative impaired FEV1 and pre-
dicted postoperative FEV1 are associated with morbidity and 
mortality after thoracic surgery.22 Numerous large studies 
documented the association of reduced pulmonary function 
with enhanced mortality in many different patient popula-
tion.23,24 Furthermore, the most frequently used parameters for 
the presurgical evaluation of thoracic-surgery candidates are 
FEV1 and the predicted postoperative FEV1.25 However, we 
have shown that there is no loss of pulmonary function post 
surgery. The average increase of FEV1 was +23.9% postsurgi-
cally. Furthermore, in a linear regression analysis the lower 
the preoperative FVC (%-predicted) or FEV1 (%-predicted) 
was, the higher the relative increase in FVC or FEV1 after 
RP was (p < 0.02 for both). Therefore, it seems that preopera-
tive FEV1 is not the best predictor of complications after RP, 
and might in isolation not be useful to guide the selection of 
surgical candidates for RP. In non–small-cell lung cancer sur-
gery, the Charlson comorbidity index was predictive of major 
postoperative complications.26 Thus, we plan to evaluate the 
Charlson comorbidity index as a possible reliable predictor 
for patient selection.
Because of the small number of patients, the differences in 
the analyses could be attributable to chance even if Bonferroni 
adjustment and effect-size calculation were applied. The results 
of this study should be confirmed in a study with larger sample 
size. We observed a rapid reaccumulation of the pleural fluid 
between thoracoscopy and RP irrespective of the underlying 
reason (entrapment or fluid accumulation). There was reaccu-
mulation of pleural fluid at different levels in all patients. There 
might be a bias because of the rapidness of pleural-fluid accu-
mulation and the influence on changes in pulmonary function 
and perfusion. Pulmonary therapists helped patients undergo-
ing RP to strengthen the pulmonary function in the preoperative 
and postoperative management. These multiple components 
included smoking cessation, intensive chest physiotherapy, 
maximal inspiratory maneuvers, and use of a flutter valve to 
facilitate mucus clearance. These confounding factors might 
have influenced the results. These aspects should be considered 
when the results of the present study are interpreted.
CONCLUSIONS
Lung-sparing RP leads to significant improvement of 
pulmonary function and perfusion after a recovery time of 
2 months. Functional results are better after preservation 
of the diaphragm. Preservation of physiological reserve via 
lung-sparing RP might allow patients with MPM to be eligible 
for further therapeutic options in the long term.
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